HC Wainwright Has Positive Estimate for MDGL FY2025 Earnings

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) – HC Wainwright increased their FY2025 earnings estimates for shares of Madrigal Pharmaceuticals in a report released on Tuesday, November 11th. HC Wainwright analyst A. Fein now expects that the biopharmaceutical company will post earnings of ($9.99) per share for the year, up from their previous estimate of ($15.41). HC Wainwright currently has a “Buy” rating and a $568.00 price target on the stock. The consensus estimate for Madrigal Pharmaceuticals’ current full-year earnings is ($23.47) per share. HC Wainwright also issued estimates for Madrigal Pharmaceuticals’ Q4 2025 earnings at ($0.07) EPS, Q1 2026 earnings at ($0.32) EPS, Q2 2026 earnings at $1.66 EPS, Q3 2026 earnings at $2.24 EPS, Q4 2026 earnings at $3.27 EPS, FY2026 earnings at $6.84 EPS, FY2027 earnings at $15.31 EPS, FY2028 earnings at $54.69 EPS and FY2029 earnings at $96.19 EPS.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last released its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported ($5.08) earnings per share for the quarter, missing the consensus estimate of ($2.01) by ($3.07). Madrigal Pharmaceuticals had a negative net margin of 54.68% and a negative return on equity of 38.38%. The company had revenue of $287.27 million during the quarter, compared to the consensus estimate of $244.33 million.

Several other research analysts have also recently weighed in on the company. Bank of America upgraded Madrigal Pharmaceuticals from an “underperform” rating to a “neutral” rating and increased their price objective for the stock from $266.00 to $445.00 in a research report on Monday, November 3rd. JMP Securities set a $527.00 target price on shares of Madrigal Pharmaceuticals in a research report on Wednesday, November 5th. Canaccord Genuity Group boosted their price target on Madrigal Pharmaceuticals from $428.00 to $526.00 and gave the company a “buy” rating in a research note on Friday, September 12th. TD Cowen lifted their price objective on Madrigal Pharmaceuticals from $390.00 to $554.00 and gave the company a “buy” rating in a report on Tuesday, August 26th. Finally, Truist Financial assumed coverage on Madrigal Pharmaceuticals in a research report on Tuesday, October 14th. They issued a “buy” rating and a $580.00 price target on the stock. Thirteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $534.08.

Madrigal Pharmaceuticals Price Performance

Shares of NASDAQ MDGL opened at $528.94 on Thursday. The business’s 50 day moving average is $442.28 and its 200-day moving average is $362.34. The firm has a market cap of $12.01 billion, a P/E ratio of -41.16 and a beta of -1.04. Madrigal Pharmaceuticals has a 1-year low of $265.00 and a 1-year high of $544.25. The company has a current ratio of 5.11, a quick ratio of 4.78 and a debt-to-equity ratio of 0.17.

Hedge Funds Weigh In On Madrigal Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in MDGL. VSM Wealth Advisory LLC acquired a new stake in Madrigal Pharmaceuticals in the first quarter valued at $25,000. Accent Capital Management LLC bought a new position in Madrigal Pharmaceuticals during the first quarter worth $25,000. AlphaQuest LLC lifted its stake in shares of Madrigal Pharmaceuticals by 412.5% in the 2nd quarter. AlphaQuest LLC now owns 82 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 66 shares during the period. Summit Securities Group LLC acquired a new stake in Madrigal Pharmaceuticals during the first quarter worth approximately $33,000. Finally, Mather Group LLC. bought a new position in shares of Madrigal Pharmaceuticals during the 3rd quarter worth approximately $33,000. 98.50% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Madrigal Pharmaceuticals

In other news, Director Kenneth Bate sold 16,575 shares of Madrigal Pharmaceuticals stock in a transaction dated Wednesday, November 5th. The stock was sold at an average price of $484.30, for a total transaction of $8,027,272.50. Following the sale, the director directly owned 2,627 shares of the company’s stock, valued at approximately $1,272,256.10. This trade represents a 86.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Bros. Advisors Lp Baker acquired 59,901 shares of the stock in a transaction dated Wednesday, August 20th. The stock was purchased at an average cost of $385.16 per share, with a total value of $23,071,469.16. Following the purchase, the director directly owned 1,947,968 shares of the company’s stock, valued at $750,279,354.88. This trade represents a 3.17% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders bought 165,683 shares of company stock worth $61,921,142 and sold 42,774 shares worth $18,450,408. 21.50% of the stock is currently owned by insiders.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.